Biomarkers for skin involvement and fibrotic activity in scleroderma

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 3, 2012, Pages 267-276

  Moinzadeh, P ^a,b   Denton, C P ^b   Abraham, D ^b   Ong, V ^b   Hunzelmann, N ^a   Eckes, B ^a   Krieg, T ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMYLOID RELATED SERUM PROTEIN A; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; COLLAGEN; COMPLEMENT FACTOR H; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; CYTOKINE; ENDOTHELIN 1; GROWTH FACTOR; HEAT SHOCK PROTEIN 70; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MESSENGER RNA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PLATELET DERIVED GROWTH FACTOR; PROTEIN; PROTEINASE; THROMBOCYTE BASIC PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CUTANEOUS PARAMETERS; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCLERODERMA; SERUM; SKIN BIOPSY; SKIN FIBROSIS; SKIN MANIFESTATION; SKINFOLD THICKNESS; STEM CELL; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; ULTRASOUND;

BIOLOGICAL MARKERS; BIOPSY; FIBROSIS; HUMANS; PROTEOMICS; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84857367158     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04206.x     Document Type: Review

References (96)

1. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205. (Pubitemid 18073738)
2. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84-88. (Pubitemid 28060123)
3. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990; 33: 1256-1263. (Pubitemid 20273315)
4. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose vs. low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445-2454.
5. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide vs. placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
6. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide vs. azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-212. (Pubitemid 43372319)
7. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-372.
8. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate vs. placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-1358. (Pubitemid 32537533)
9. Das SN, Alam MR, Islam N, et al. Placebo controlled trial of methotrexate in systemic sclerosis. Mymensingh Med J 2005; 14: 71-74.
10. van Laar JM, Farge D, Tyndall A. Stem cell transplantation: a treatment option for severe systemic sclerosis? Ann Rheum Dis 2008; 67 (Suppl. 3): iii35-iii38.
11. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979; 22: 130-140. (Pubitemid 9156666)
12. Pope JE, Baron M, Bellamy N, et al. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol 1995; 22: 1271-1276.
13. Silman A, Harrison M, Brennan P. Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma. J Rheumatol 1995; 22: 1277-1280.
14. Czirjak L, Foeldvari I, Muller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology (Oxford) 2008; 47 (Suppl. 5): v44-v45.
15. Akesson A, Hesselstrand R, Scheja A, Wildt M. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann Rheum Dis 2004; 63: 791-796. (Pubitemid 38850449)
16. Hesselstrand R, Scheja A, Wildt M, Akesson A. High-frequency ultrasound of skin involvement in systemic sclerosis reflects oedema, extension and severity in early disease. Rheumatology (Oxford) 2008; 47: 84-87. (Pubitemid 350286269)
17. Madani G, Katz RD, Haddock JA, Denton CP, Bell JR. The role of radiology in the management of systemic sclerosis. Clin Radiol 2008; 63: 959-967.
18. Nives Parodi M, Castagneto C, Filaci G, et al. Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. Br J Rheumatol 1997; 36: 244-250.
19. Kissin EY, Schiller AM, Gelbard RB, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006; 55: 603-609. (Pubitemid 44289881)
20. Merkel PA, Silliman NP, Denton CP, et al. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum 2008; 59: 699-705. (Pubitemid 351679546)
21. Aghassi D, Monoson T, Braverman I. Reproducible measurements to quantify cutaneous involvement in scleroderma. Arch Dermatol 1995; 131: 1160-1166.
22. Falanga V, Bucalo B. Use of a durometer to assess skin hardness. J Am Acad Dermatol 1993; 29: 47-51. (Pubitemid 23197194)
23. Enomoto DN, Mekkes JR, Bossuyt PM, Hoekzema R, Bos JD. Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma. J Am Acad Dermatol 1996; 35: 381-387. (Pubitemid 26299226)
24. Balbir-Gurman A, Denton CP, Nichols B, et al. Non-invasive measurement of biomechanical skin properties in systemic sclerosis. Ann Rheum Dis 2002; 61: 237-241. (Pubitemid 34177754)
25. Kuwahara Y, Shima Y, Shirayama D, et al. Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure. Rheumatology (Oxford) 2008; 47: 1018-1024. (Pubitemid 351865926)
26. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987; 247: 597-604. (Pubitemid 17158405)
27. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-567. (Pubitemid 46348510)
28. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994; 37: 278-288.
29. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-827.
30. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47-51. (Pubitemid 28086062)
31. Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005; 44: 1518-1524. (Pubitemid 41742468)
32. de Winter P, Leoni P, Abraham D. Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein. Growth Factors 2008; 26: 80-91. (Pubitemid 351584060)
33. Dziadzio M, Usinger W, Leask A, et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM 2005; 98: 485-492. (Pubitemid 41418671)
34. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 2009; 3: 89-94.
35. Abraham D. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology (Oxford) 2008; 47 (Suppl. 5): v8-v9.
36. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-2676.
37. Gabrielli A, Svegliati S, Moroncini G, Luchetti M, Tonnini C, Avvedimento EV. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun Rev 2007; 7: 121-126. (Pubitemid 350116724)
38. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253-1260. (Pubitemid 29218295)
39. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008; 47 (Suppl. 5): v2-v4.
40. Yanaba K, Komura K, Kodera M, et al. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 2006; 65: 124-126. (Pubitemid 41815654)
41. Yamamoto T. Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis. Clin Exp Rheumatol 2003; 21: 369-375. (Pubitemid 36747837)
42. Distler JH, Akhmetshina A, Schett G, Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48: 98-103.
43. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30: 231-237.
44. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201. (Pubitemid 43122202)
45. Matsushita T, Fujimoto M, Hasegawa M, et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007; 34: 2056-2062. (Pubitemid 47548210)
46. Matsushita T, Hasegawa M, Matsushita Y, et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007; 16: 87-93. (Pubitemid 46040484)
47. Farina G, Lemaire R, Korn JH, Widom RL. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 2006; 25: 213-222. (Pubitemid 43729069)
48. Farina G, Lemaire R, Pancari P, Bayle J, Widom RL, Lafyatis R. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 2009; 68: 435-441.
49. Hesselstrand R, Kassner A, Heinegard D, Saxne T. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis 2008; 67: 1242-1248.
50. Gheita TA, Hussein H. Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap. Joint Bone Spine 2011; Apr 14 [Epub ahead of print].
51. Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
52. Takemura H, Suzuki H, Fujisawa H, et al. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 1998; 25: 1534-1539. (Pubitemid 28364759)
53. Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to 36 months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
54. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140-146. (Pubitemid 32781022)
55. Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138: 540-546. (Pubitemid 39573637)
56. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-284. (Pubitemid 43209303)
57. Fuschiotti P, Medsger TA Jr, Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009; 60: 1119-1128.
58. Ogawa F, Shimizu K, Hara T, et al. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol 2008; 26: 659-662.
59. Iwata Y, Yoshizaki A, Ogawa F, et al. Increased serum pentraxin 3 in patients with systemic sclerosis. J Rheumatol 2009; 36: 976-983.
60. Masui Y, Asano Y, Shibata S, et al. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2011; DOI: [Epub ahead of print].
61. Carlo-Stella N, Belloli L, Biondi ML, Marasini B. Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis? Clin Rheumatol 2009; 28: 241-242.
62. Scheja A, Wildt M, Wollheim FA, Akesson A, Saxne T. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 2000; 39: 1110-1113.
63. Krieg T, Langer I, Gerstmeier H, et al. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 1986; 87: 788-791. (Pubitemid 17186423)
64. Heickendorff L, Parvez A, Bjerring P, Halkier-Sorensen L, Zachariae H. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up - investigations in subclasses and during therapy. Acta Derm Venereol 1991; 71: 185-188.
65. Diot E, Diot P, Valat C, et al. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Eur Respir J 1995; 8: 1559-1565.
66. Zachariae H, Halkier-Sorensen L, Heickendorff L. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma. Acta Derm Venereol 1989; 69: 66-70. (Pubitemid 19028335)
67. Nagy Z, Czirjak L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005; 23: 165-172. (Pubitemid 40662995)
68. Scheja A, Akesson A, Horslev-Petersen K. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scand J Rheumatol 1992; 21: 5-9.
69. Hunzelmann N, Risteli J, Risteli L, et al. Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma? Br J Dermatol 1998; 139: 1020-1025. (Pubitemid 29010539)
70. Dziadzio M, Smith RE, Abraham DJ, et al. Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol 2004; 22: 356-367. (Pubitemid 38585242)
71. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584. (Pubitemid 32493984)
72. Akimoto S, Hayashi H, Ishikawa H. Disaccharide analysis of the skin glycosaminoglycans in systemic sclerosis. Br J Dermatol 1992; 126: 29-34.
73. Higuchi T, Ohnishi K, Hayashi H, Ishikawa O, Miyachi Y. Changes in skin disaccharide components correlate with the severity of sclerotic skin in systemic sclerosis. Acta Derm Venereol 1994; 74: 179-182. (Pubitemid 24163589)
74. Gotting C, Sollberg S, Kuhn J, et al. Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis. J Invest Dermatol 1999; 112: 919-924. (Pubitemid 29277993)
75. Gotting C, Kuhn J, Sollberg S, et al. Elevated serum xylosyltransferase activity correlates with a high level of hyaluronate in patients with systemic sclerosis. Acta Derm Venereol 2000; 80: 60-61. (Pubitemid 30110859)
76. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010; 37: 11-25.
77. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289: 567-572. (Pubitemid 27477648)
78. Kim WU, Min SY, Cho ML, et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 2005; 7: R71-R79.
79. Yazawa N, Kikuchi K, Ihn H, et al. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol 2000; 42: 70-75. (Pubitemid 30470322)
80. Asano Y, Ihn H, Kubo M, et al. Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 303-307. (Pubitemid 43372845)
81. Moinzadeh P, Krieg T, Hellmich M, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol 2011; Jun 26 [Epub ahead of print].
82. Scambi C, La Verde V, De Franceschi L, et al. Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H. PLoS ONE 2010; 5: e12162.
83. Guerranti R, Bertocci E, Fioravanti A, et al. Serum proteome of patients with systemic sclerosis: molecular analysis of expression and prevalence of haptoglobin alpha chain isoforms. Int J Immunopathol Pharmacol 2010; 23: 901-909.
84. Pendergrass SA, Hayes E, Farina G, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS ONE 2010; 5: e12106.
85. Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58: 1465-1474. (Pubitemid 351705936)
86. Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58: 1475-1484. (Pubitemid 351705937)
87. Chan ES, Fernandez P, Merchant AA, et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006; 54: 2632-2642. (Pubitemid 44205026)
88. Manetti M, Ibba-Manneschi L, Liakouli V, et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 598-605.
89. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130: 694-705.
90. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008; 3: e2696.
91. Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-588.
92. Brinckmann J, Kim S, Wu J, et al. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol 2005; 24: 459-468. (Pubitemid 41443273)
93. Clements PJ. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995; 7: 517-521.
94. Kaldas M, Khanna PP, Furst DE, et al. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis - assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford) 2009; 48: 1143-1146.
95. Moore TL, Lunt M, McManus B, Anderson ME, Herrick AL. Seventeen-point dermal ultrasound scoring system - a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42: 1559-1563. (Pubitemid 37508932)
96. Kaloudi O, Bandinelli F, Filippucci E, et al. High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis. Ann Rheum Dis 2010; 69: 1140-1143.